持续自动化胰岛素输注与传感器及泵治疗在低血糖高风险1型糖尿病成人中的安全性和有效性:一项随机对照试验
研究纳入72例低血糖高风险的1型糖尿病成人,按2:1随机接受自动化胰岛素输注(AID)或传感器及泵治疗12周。AID组目标范围内时间(TIR)较传感器及泵组升高8.6%,低于目标范围时间(TBR)降低3.7%,且疗效在延长期内得以维持。
要点
- AID较传感器及泵治疗显著降低TBR 3.7%(95%CI -4.8, -2.6),P<0.001。
- AID较传感器及泵治疗显著升高TIR 8.6%(95%CI 5.2, 12.1),P<0.001。
- AID组发生2例严重低血糖事件,作者强烈推荐该特定人群使用AID。
核心结论
- 在低血糖高风险的1型糖尿病成人中,AID较传感器及泵治疗使TBR所量化的低血糖风险降低超过两倍,同时改善TIR并减少高血糖;作者强烈推荐该特定人群使用AID。
研究设计与样本
- 平行组随机对照试验(2:1),纳入72例使用胰岛素泵、Clarke低血糖感知觉量表评分>3分和/或既往6个月内发生严重低血糖并经2周盲法持续葡萄糖监测证实TBR(传感器葡萄糖<70 mg/dL)至少5%的1型糖尿病成人。
- 干预为Tandem t:slim ×2 with Control-IQ技术的AID对比传感器及泵治疗,疗程12周;所有参与者可选参加12周AID延长期。
主要发现
- AID组较传感器及泵组TBR降低3.7%(95%CI -4.8, -2.6),P<0.001。
- AID组较传感器及泵组TIR升高8.6%(95%CI 5.2, 12.1),P<0.001。
- AID组较传感器及泵组TAR降低5.3%(95%CI -87.7, -1.8),P=0.004。
- AID组与传感器及泵组的平均传感器葡萄糖读数相似。
- 在12周延长期内,AID组疗效得以维持,传感器及泵组中亦重现该疗效;使用AID期间发生2例严重低血糖事件。
关键数值与推荐
- TBR定义为传感器葡萄糖读数<70 mg/dL。
- TIR定义为70-180 mg/dL。
- 作者结论为强烈推荐该特定人群使用AID。
临床怎么用
- 作者强烈推荐在低血糖高风险的1型糖尿病成人中使用AID。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Assess the safety and efficacy of automated insulin delivery (AID) in adults with type 1 diabetes (T1D) at high risk for hypoglycemia. RESEARCH DESIGN AND METHODS: Participants were 72 adults with T1D who used an insulin pump with Clarke Hypoglycemia Perception Awareness scale score >3 and/or had severe hypoglycemia during the previous 6 months confirmed by time below range (TBR; defined as sensor glucose [SG] reading <70 mg/dL) of at least 5% during 2 weeks of blinded continuous glucose monitoring (CGM). Parallel-arm, randomized trial (2:1) of AID (Tandem t:slim ×2 with Control-IQ technology) versus CGM and pump therapy for 12 weeks. The primary outcome was TBR change from baseline. Secondary outcomes included time in target range (TIR; 70-180 mg/dL), time above range (TAR), mean SG reading, and time with glucose level <54 mg/dL. An optional 12-week extension with AID was offered to all participants. RESULTS: Compared with the sensor and pump (S&P), AID resulted in significant reduction of TBR by -3.7% (95% CI -4.8, -2.6), P < 0.001; an 8.6% increase in TIR (95% CI 5.2, 12.1), P < 0.001; and a -5.3% decrease in TAR (95% CI -87.7, -1.8), P = 0.004. Mean SG reading remained similar in the AID and S&P groups. During the 12-week extension, the effects of AID were sustained in the AID group and reproduced in the S&P group. Two severe hypoglycemic episodes occurred using AID. CONCLUSIONS: In adults with T1D at high risk for hypoglycemia, AID reduced the risk for hypoglycemia more than twofold, as quantified by TBR, while improving TIR and reducing hyperglycemia. Hence, AID is strongly recommended for this specific population.
引用
- Renard E, Joubert M, Villard O, et al. Safety and Efficacy of Sustained Automated Insulin Delivery Compared With Sensor and Pump Therapy in Adults With Type 1 Diabetes at High Risk for Hypoglycemia: A Randomized Controlled Trial. Diabetes Care. 2023. PMID: 37729080. doi:10.2337/dc23-0685
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。